Author

Xuewen Pan

Tango Therapeutics (United States)ORCID 0000-0002-0148-5631Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Genetics· 1 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:benchmarking· 2 Assay:CRISPR screen· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Alan HuangiD· 3 shared Binzhang SheniD· 2 shared Hannah StoweiD· 2 shared Jannik N. AnderseniD· 2 shared Minjie ZhangiD· 2 shared Samuel R. MeieriD· 2 shared Shangtao LiuiD· 2 shared Tenzing KhenduiD· 2 shared

Activity by Year

2020-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersGenomics

Alan HuangORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

GenomicsCell Reports MethodsPeer-reviewedJun 1, 2026

Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens

Silvia Fenoglio, Yi Yu, James Tepper…·Teng Teng

This paper introduces CRISPR-StAR, an in vivo CRISPR screening platform with improved normalization and analysis tools, showing it can identify tumor suppressor gene effects not observable in vitro.

1 citation

humanCRISPR screen

𝕏 PostBluesky

Cancer BiologyBiochimica et Biophysica Acta (BBA) - Molecular Cell ResearchPeer-reviewedOct 15, 2025

Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancer

Hongxiang Zhang, Matthew R. Tonini, Lauren Catherine M. Martires…·Teng Teng

The paper identifies HBS1L as a synthetic lethal target in FOCAD-deleted cancer through combinatorial CRISPR screens and validates its dependency via genetic manipulation and in vivo experiments.

2 citations

humangenetic perturbation / CRISPR

𝕏 PostBluesky

GeneticsNature BiotechnologyPeer-reviewedJul 13, 2020

Optimization of AsCas12a for combinatorial genetic screens in human cells

Peter C. DeWeirdt, Kendall R Sanson, Annabel K. Sangree…·John G. Doench

This paper optimizes AsCas12a for combinatorial genetic screens in human cells by improving on-target and off-target activity and enabling higher-order multiplexing.

219 citationstop 1%

humanCRISPR screen

𝕏 PostBluesky